Targeting Circadian Clock Dysfunction in Alzheimer’s Disease
DC1 Proteolysis Targeting Chimeras for Targeted Degradation of Protein Kinases Regulating Circadian Rhythm in AD
DC2 Circadian Polypharmacology in AD: Discovery of Multitarget-Directed Ligands
DC3 An Innovative Data-Driven Drug Discovery Platform for Alzheimer’s Disease
DC4 Structure and Ligand-Based Strategies to Discover Orexin Receptor Modulators Targeting the Circadian Clock and AD
DC5 Hit Selection Strategies for Identification of Kinase Inhibitors Modulating Circadian Rhythm in AD
DC6 Nanocarriers for Anti-Alzheimer SiRNAs Delivery to the Brain
DC7 Circadian Control of Behaviour Associated with Alzheimer’s Disease Somatic Mutations Impacting the Cytoskeleton
DC8 Design of Multi-Functionalized Nano-Drug Delivery System for AD
DC9 Action of Molecules Targeting Circadian Rhythm Pathways in Hydrogel-Based 3d In Vitro Models Relevant for AD
DC10 Blood Brain Barrier (Bbb) and Organ-On-Chip Model to Study AD
DC11 Development and Application of Photoswitchable Orexin Receptor Ligands for Control of Circadian Rhythm in AD
DC12 Targeting Epigenetic Control of Clock Genes in Neural Stem Cells (NSCS)
DC13 Role of Circadian Clock Dysfunction on Inflammation Mechanisms in AD
DC14 Circadian Control of Mitochondria-Specific Autophagy in Neuronal Degeneration Associated with AD
DC15 Technology-Tailored Commercialization of Drug Development for AD
DC16 Development Circadian Rhythm-Based Drug Repurposing Strategy for AD
DC17 Circadian Control of Alzheimer’s Disease in Drosophila Melanogaster
